Expertise in
3
conditions

Dr. Mili Arora

Hematology
Office
4501 X St Ste 3016, 
Sacramento, CA 
Offers Telehealth
17 Years of Experience
Expertise in
3
conditions
Office
4501 X St Ste 3016, 
Sacramento, CA 

Overview

Mili Arora is a Hematologist practicing medicine in Sacramento, California. She has been practicing medicine for over 17 years.

Dr. Arora is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Febrile Neutropenia, Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, Burkitt Lymphoma, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 7 clinical trials.

Graduate Year

2009

Specialties

Hematology

Licenses

Internal Medicine in CA

Hospital Affiliations

Marshall Medical Center
University Of California Davis Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Office
4501 X St Ste 3016, Sacramento, CA 95817

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug
Study Drugs: carboplatin, paclitaxel, atezolizumab
Study Phase: Phase 2
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Other, Radiation, Drug
Study Drug: Paclitaxel
Study Phase: Phase 2
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Enobosarm, Pembrolizumab
Study Phase: Phase 2
View 6 Less Clinical Trials

16 Total Publications

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 30, 2026
Similar Doctors
Expertise in
30
conditions
Dr. Brian Jonas
Hematology | Oncology
Expertise in
30
conditions
Dr. Brian Jonas
Hematology | Oncology
Referral may be required

Office

4501 X St Ste 3016, 
Sacramento, CA 
 (0.1 miles away)
916-734-5981
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brian Jonas is a Hematologist and an Oncologist practicing medicine in Sacramento, California. Dr. Jonas is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
13
conditions
Dr. Karen L. Kelly
Hematology | Oncology
Expertise in
13
conditions
Dr. Karen L. Kelly
Hematology | Oncology
Referral may be required

UC Davis Comprehensive Cancer Center

2279 45th St, 
Sacramento, CA 
 (0.1 miles away)
916-734-5959
Languages Spoken:
English

Karen Kelly is a Hematologist and an Oncologist practicing medicine in Sacramento, California. Dr. Kelly is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Office

4501 X St Ste 3016, 
Sacramento, CA 
 (0.1 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adam Giermasz is a Hematologist practicing medicine in Sacramento, California. Dr. Giermasz is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Hemophilia B, Hemophilia A, Blood Clots, Hemophilic Arthropathy, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Mili Arora

How do I make an appointment with Dr. Mili Arora?

You can book an appointment with Dr. Mili Arora by calling their office at 916-734-5959. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mili Arora a top-rated expert for Febrile Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mili Arora is classified as an Advanced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mili Arora specialize in?

While Dr. Mili Arora is a Hematology, they have specific expertise in Febrile Neutropenia, Diffuse Large B-Cell Lymphoma (DLBCL), and Large-Cell Immunoblastic Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mili Arora participate in research or clinical trials?

Yes. Dr. Mili Arora has published 16 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Dr. Mili Arora's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mili Arora accept my insurance?

Dr. Mili Arora accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 916-734-5959 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arora's expertise for a condition
ConditionClose
      View All 41 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile